DK175591B1 - Farmaceutisk præparat med kontrolleret absorption af diltiazem og fremgangsmåde til fremstilling deraf - Google Patents

Farmaceutisk præparat med kontrolleret absorption af diltiazem og fremgangsmåde til fremstilling deraf Download PDF

Info

Publication number
DK175591B1
DK175591B1 DK198805756A DK575688A DK175591B1 DK 175591 B1 DK175591 B1 DK 175591B1 DK 198805756 A DK198805756 A DK 198805756A DK 575688 A DK575688 A DK 575688A DK 175591 B1 DK175591 B1 DK 175591B1
Authority
DK
Denmark
Prior art keywords
diltiazem
hours
released
measurement
total
Prior art date
Application number
DK198805756A
Other languages
Danish (da)
English (en)
Other versions
DK575688D0 (da
DK575688A (da
Inventor
Seamus Mulligan
Edward James Geoghegan
Donald Eugene Panoz
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE872790A external-priority patent/IE872790L/xx
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Publication of DK575688D0 publication Critical patent/DK575688D0/da
Publication of DK575688A publication Critical patent/DK575688A/da
Application granted granted Critical
Publication of DK175591B1 publication Critical patent/DK175591B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK198805756A 1987-10-16 1988-10-14 Farmaceutisk præparat med kontrolleret absorption af diltiazem og fremgangsmåde til fremstilling deraf DK175591B1 (da)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
IE279187 1987-10-16
IE872790A IE872790L (en) 1987-10-16 1987-10-16 Diltiazem formulation
IE279087 1987-10-16
IE279187 1987-10-16
IE315887 1987-11-20
IE315887 1987-11-20
IE82288 1988-03-18
IE82288 1988-03-18

Publications (3)

Publication Number Publication Date
DK575688D0 DK575688D0 (da) 1988-10-14
DK575688A DK575688A (da) 1989-04-17
DK175591B1 true DK175591B1 (da) 2004-12-13

Family

ID=27452034

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198805756A DK175591B1 (da) 1987-10-16 1988-10-14 Farmaceutisk præparat med kontrolleret absorption af diltiazem og fremgangsmåde til fremstilling deraf

Country Status (10)

Country Link
EP (2) EP0856313A1 (xx)
JP (1) JPH07116044B2 (xx)
KR (1) KR970001656B1 (xx)
AT (1) ATE241987T1 (xx)
AU (2) AU615221B2 (xx)
DE (1) DE3856555T2 (xx)
DK (1) DK175591B1 (xx)
ES (1) ES2194832T3 (xx)
NZ (1) NZ226575A (xx)
PT (1) PT88776B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
EP0585355B1 (en) * 1991-05-20 1995-03-22 Marion Laboratories, Inc. Multi-layered controlled release formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
ZA933725B (en) * 1992-05-28 1993-12-15 Elan Corp Plc Tablet formulation
US5523095A (en) * 1993-12-15 1996-06-04 Eastman Chemical Company Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends
US5536505A (en) * 1993-12-15 1996-07-16 Eastman Chemical Company Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
NZ270078A (en) * 1994-12-06 1998-05-27 Bernard Charles Sherman Diltiazem hydrochloride formulation comprising beads with immediate, intermediate, and delayed release dissolution profiles
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US7108866B1 (en) * 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
CN1419446A (zh) * 2000-01-27 2003-05-21 田边制药株式会社 缓释制剂及其制法
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
EP1743638A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Pharmaceutical formulations of substituted pyrazoline compounds
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
JP7048770B2 (ja) 2018-06-18 2022-04-05 アムニール コンプレックス プロダクツ リサーチ エルエルシー ピリドスチグミンを含む持続放出組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5867616A (ja) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd 腸溶性マイクロカプセル
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
JPS62114910A (ja) * 1985-11-13 1987-05-26 エラン　コ−ポレ−シヨン　ピ−　エル　シ− 吸収がコントロ−ルされた医薬製剤
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition

Also Published As

Publication number Publication date
ES2194832T3 (es) 2003-12-01
NZ226575A (en) 1991-01-29
KR970001656B1 (ko) 1997-02-13
AU615221B2 (en) 1991-09-26
EP0320097A1 (en) 1989-06-14
EP0320097B1 (en) 2003-06-04
PT88776B (pt) 1992-12-31
EP0856313A1 (en) 1998-08-05
AU7943591A (en) 1991-09-12
JPH01132521A (ja) 1989-05-25
DK575688D0 (da) 1988-10-14
KR890006240A (ko) 1989-06-12
AU2377588A (en) 1989-06-08
JPH07116044B2 (ja) 1995-12-13
AU634660B2 (en) 1993-02-25
DE3856555D1 (de) 2003-07-10
DE3856555T2 (de) 2004-04-29
ATE241987T1 (de) 2003-06-15
DK575688A (da) 1989-04-17

Similar Documents

Publication Publication Date Title
US5002776A (en) Controlled absorption diltiazem formulations
DK175591B1 (da) Farmaceutisk præparat med kontrolleret absorption af diltiazem og fremgangsmåde til fremstilling deraf
EP0149920B1 (en) Pharmaceutical formulation
US5616345A (en) Controlled absorption diltiazen formulation for once-daily administration
US4894240A (en) Controlled absorption diltiazem formulation for once-daily administration
KR940000100B1 (ko) 메토프롤롤염을 함유하는 서방형 제제의 제조방법
US4713247A (en) Long-acting formulation of cefaclor
CA2348090C (en) Oral pulsed dose drug delivery system
KR100812832B1 (ko) 다입자 변형 방출 조성물
KR101090719B1 (ko) 프로프라놀롤의 시간조절-지속 방출성 다중-과립형 투여 형태
PL188834B1 (pl) Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji
PH27176A (en) Pharmaceutical compositions containing dipyridamole or mopidamole and O-acetylsalicyclic acid or the physiologically acceptable salts thereof
NZ232030A (en) Sustained release pharmaceutical pellet composition; theophylline compound core, coated to allow faster release rate in intestine
JP2003510346A (ja) 新規医薬組成物
KR20090029830A (ko) 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
EP1267879A2 (en) Sustained release beadlets containing stavudine
US6267990B1 (en) Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient
AU2008365126A1 (en) Tamsulosin pellets for fixed dose combination
WO2004024128A2 (en) Modified release ketoprofen dosage form
RU2678324C2 (ru) Составы лоразепама с замедленным высвобождением
US6984402B2 (en) Chrono delivery formulations and method of treating atrial fibrillation
IE84002B1 (en) Diltiazem formulation
CZ146494A3 (en) Ipsapirone healing preparation
JPS59184126A (ja) ２，６−ビス−ジエタノ−ルアミノ−４，８−ジピペリジノ−ピリミド〔５，４−ｄ〕ピリミジン含有医薬組成物

Legal Events

Date Code Title Description
PUP Patent expired